Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.
Identifieur interne : 000275 ( Main/Corpus ); précédent : 000274; suivant : 000276Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.
Auteurs : Helmut Uphoff ; Matthias An Der Heiden ; Brunhilde Schweiger ; Hartmut Campe ; Dietmar Beier ; Carina Helmeke ; Martina Littmann ; Walter Haas ; Silke Buda ; Daniel Faensen ; Marcel Feig ; Doris Altmann ; Ole Wichmann ; Tim Eckmanns ; Udo BuchholzSource :
- PloS one [ 1932-6203 ] ; 2011.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (therapeutic use), Adolescent (MeSH), Adult (MeSH), Age Distribution (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Case-Control Studies (MeSH), Child (MeSH), Child, Preschool (MeSH), Female (MeSH), Germany (epidemiology), Humans (MeSH), Infant (MeSH), Infant, Newborn (MeSH), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (immunology), Influenza Vaccines (therapeutic use), Influenza, Human (drug therapy), Influenza, Human (epidemiology), Influenza, Human (immunology), Influenza, Human (virology), Logistic Models (MeSH), Male (MeSH), Middle Aged (MeSH), Multivariate Analysis (MeSH), Pandemics (prevention & control), Treatment Outcome (MeSH), Vaccination (MeSH), Young Adult (MeSH).
- MESH :
- chemical , immunology : Influenza Vaccines.
- chemical , therapeutic use : Adjuvants, Immunologic, Influenza Vaccines.
- geographic , epidemiology : Germany.
- drug therapy : Influenza, Human.
- epidemiology : Influenza, Human.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza, Human.
- prevention & control : Pandemics.
- virology : Influenza, Human.
- Adolescent, Adult, Age Distribution, Aged, Aged, 80 and over, Case-Control Studies, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Logistic Models, Male, Middle Aged, Multivariate Analysis, Treatment Outcome, Vaccination, Young Adult.
Abstract
During the autumn wave of the pandemic influenza virus A/(H1N1) 2009 (pIV) the German population was offered an AS03-adjuvanted vaccine. The authors compared results of two methods calculating the effectiveness of the vaccine (VE). The test-negative case-control method used data from virologic surveillance including influenza-positive and negative patients. An innovative case-series methodology explored data from all nationally reported laboratory-confirmed influenza cases. The proportion of reported cases occurring in vaccinees during an assumed unprotected phase after vaccination was compared with that occurring in vaccinees during their assumed protected phase. The test-negative case-control method included 1,749 pIV cases and 2,087 influenza test-negative individuals of whom 6 (0.3%) and 36 (1.7%), respectively, were vaccinated. The case series method included data from 73,280 cases. VE in the two methods was 79% (95% confidence interval (CI) = 35-93%; P = 0.007) and 87% (95% CI = 78-92%; P<0.001) for individuals less than 14 years of age and 70% (95% CI = -45%-94%, P = 0.13) and 74% (95% CI = 64-82%; P<0.001) for individuals above the age of 14. Both methods yielded similar VE in both age groups; and VE for the younger age group seemed to be higher.
DOI: 10.1371/journal.pone.0019932
PubMed: 21789163
PubMed Central: PMC3138735
Links to Exploration step
pubmed:21789163Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.</title><author><name sortKey="Uphoff, Helmut" sort="Uphoff, Helmut" uniqKey="Uphoff H" first="Helmut" last="Uphoff">Helmut Uphoff</name><affiliation><nlm:affiliation>Hessisches Landes Prüfungs - und Untersuchungsamt im Gesundheitswesen, Dillenburg, Germany. h.uphoff@hlpug.hessen.de</nlm:affiliation></affiliation></author><author><name sortKey="An Der Heiden, Matthias" sort="An Der Heiden, Matthias" uniqKey="An Der Heiden M" first="Matthias" last="An Der Heiden">Matthias An Der Heiden</name></author><author><name sortKey="Schweiger, Brunhilde" sort="Schweiger, Brunhilde" uniqKey="Schweiger B" first="Brunhilde" last="Schweiger">Brunhilde Schweiger</name></author><author><name sortKey="Campe, Hartmut" sort="Campe, Hartmut" uniqKey="Campe H" first="Hartmut" last="Campe">Hartmut Campe</name></author><author><name sortKey="Beier, Dietmar" sort="Beier, Dietmar" uniqKey="Beier D" first="Dietmar" last="Beier">Dietmar Beier</name></author><author><name sortKey="Helmeke, Carina" sort="Helmeke, Carina" uniqKey="Helmeke C" first="Carina" last="Helmeke">Carina Helmeke</name></author><author><name sortKey="Littmann, Martina" sort="Littmann, Martina" uniqKey="Littmann M" first="Martina" last="Littmann">Martina Littmann</name></author><author><name sortKey="Haas, Walter" sort="Haas, Walter" uniqKey="Haas W" first="Walter" last="Haas">Walter Haas</name></author><author><name sortKey="Buda, Silke" sort="Buda, Silke" uniqKey="Buda S" first="Silke" last="Buda">Silke Buda</name></author><author><name sortKey="Faensen, Daniel" sort="Faensen, Daniel" uniqKey="Faensen D" first="Daniel" last="Faensen">Daniel Faensen</name></author><author><name sortKey="Feig, Marcel" sort="Feig, Marcel" uniqKey="Feig M" first="Marcel" last="Feig">Marcel Feig</name></author><author><name sortKey="Altmann, Doris" sort="Altmann, Doris" uniqKey="Altmann D" first="Doris" last="Altmann">Doris Altmann</name></author><author><name sortKey="Wichmann, Ole" sort="Wichmann, Ole" uniqKey="Wichmann O" first="Ole" last="Wichmann">Ole Wichmann</name></author><author><name sortKey="Eckmanns, Tim" sort="Eckmanns, Tim" uniqKey="Eckmanns T" first="Tim" last="Eckmanns">Tim Eckmanns</name></author><author><name sortKey="Buchholz, Udo" sort="Buchholz, Udo" uniqKey="Buchholz U" first="Udo" last="Buchholz">Udo Buchholz</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21789163</idno><idno type="pmid">21789163</idno><idno type="doi">10.1371/journal.pone.0019932</idno><idno type="pmc">PMC3138735</idno><idno type="wicri:Area/Main/Corpus">000275</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000275</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.</title><author><name sortKey="Uphoff, Helmut" sort="Uphoff, Helmut" uniqKey="Uphoff H" first="Helmut" last="Uphoff">Helmut Uphoff</name><affiliation><nlm:affiliation>Hessisches Landes Prüfungs - und Untersuchungsamt im Gesundheitswesen, Dillenburg, Germany. h.uphoff@hlpug.hessen.de</nlm:affiliation></affiliation></author><author><name sortKey="An Der Heiden, Matthias" sort="An Der Heiden, Matthias" uniqKey="An Der Heiden M" first="Matthias" last="An Der Heiden">Matthias An Der Heiden</name></author><author><name sortKey="Schweiger, Brunhilde" sort="Schweiger, Brunhilde" uniqKey="Schweiger B" first="Brunhilde" last="Schweiger">Brunhilde Schweiger</name></author><author><name sortKey="Campe, Hartmut" sort="Campe, Hartmut" uniqKey="Campe H" first="Hartmut" last="Campe">Hartmut Campe</name></author><author><name sortKey="Beier, Dietmar" sort="Beier, Dietmar" uniqKey="Beier D" first="Dietmar" last="Beier">Dietmar Beier</name></author><author><name sortKey="Helmeke, Carina" sort="Helmeke, Carina" uniqKey="Helmeke C" first="Carina" last="Helmeke">Carina Helmeke</name></author><author><name sortKey="Littmann, Martina" sort="Littmann, Martina" uniqKey="Littmann M" first="Martina" last="Littmann">Martina Littmann</name></author><author><name sortKey="Haas, Walter" sort="Haas, Walter" uniqKey="Haas W" first="Walter" last="Haas">Walter Haas</name></author><author><name sortKey="Buda, Silke" sort="Buda, Silke" uniqKey="Buda S" first="Silke" last="Buda">Silke Buda</name></author><author><name sortKey="Faensen, Daniel" sort="Faensen, Daniel" uniqKey="Faensen D" first="Daniel" last="Faensen">Daniel Faensen</name></author><author><name sortKey="Feig, Marcel" sort="Feig, Marcel" uniqKey="Feig M" first="Marcel" last="Feig">Marcel Feig</name></author><author><name sortKey="Altmann, Doris" sort="Altmann, Doris" uniqKey="Altmann D" first="Doris" last="Altmann">Doris Altmann</name></author><author><name sortKey="Wichmann, Ole" sort="Wichmann, Ole" uniqKey="Wichmann O" first="Ole" last="Wichmann">Ole Wichmann</name></author><author><name sortKey="Eckmanns, Tim" sort="Eckmanns, Tim" uniqKey="Eckmanns T" first="Tim" last="Eckmanns">Tim Eckmanns</name></author><author><name sortKey="Buchholz, Udo" sort="Buchholz, Udo" uniqKey="Buchholz U" first="Udo" last="Buchholz">Udo Buchholz</name></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (therapeutic use)</term><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Age Distribution (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Case-Control Studies (MeSH)</term><term>Child (MeSH)</term><term>Child, Preschool (MeSH)</term><term>Female (MeSH)</term><term>Germany (epidemiology)</term><term>Humans (MeSH)</term><term>Infant (MeSH)</term><term>Infant, Newborn (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (immunology)</term><term>Influenza Vaccines (therapeutic use)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (virology)</term><term>Logistic Models (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Multivariate Analysis (MeSH)</term><term>Pandemics (prevention & control)</term><term>Treatment Outcome (MeSH)</term><term>Vaccination (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Germany</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Distribution</term><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Humans</term><term>Infant</term><term>Infant, Newborn</term><term>Logistic Models</term><term>Male</term><term>Middle Aged</term><term>Multivariate Analysis</term><term>Treatment Outcome</term><term>Vaccination</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">During the autumn wave of the pandemic influenza virus A/(H1N1) 2009 (pIV) the German population was offered an AS03-adjuvanted vaccine. The authors compared results of two methods calculating the effectiveness of the vaccine (VE). The test-negative case-control method used data from virologic surveillance including influenza-positive and negative patients. An innovative case-series methodology explored data from all nationally reported laboratory-confirmed influenza cases. The proportion of reported cases occurring in vaccinees during an assumed unprotected phase after vaccination was compared with that occurring in vaccinees during their assumed protected phase. The test-negative case-control method included 1,749 pIV cases and 2,087 influenza test-negative individuals of whom 6 (0.3%) and 36 (1.7%), respectively, were vaccinated. The case series method included data from 73,280 cases. VE in the two methods was 79% (95% confidence interval (CI) = 35-93%; P = 0.007) and 87% (95% CI = 78-92%; P<0.001) for individuals less than 14 years of age and 70% (95% CI = -45%-94%, P = 0.13) and 74% (95% CI = 64-82%; P<0.001) for individuals above the age of 14. Both methods yielded similar VE in both age groups; and VE for the younger age group seemed to be higher.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21789163</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>7</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.</ArticleTitle><Pagination><MedlinePgn>e19932</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0019932</ELocationID><Abstract><AbstractText>During the autumn wave of the pandemic influenza virus A/(H1N1) 2009 (pIV) the German population was offered an AS03-adjuvanted vaccine. The authors compared results of two methods calculating the effectiveness of the vaccine (VE). The test-negative case-control method used data from virologic surveillance including influenza-positive and negative patients. An innovative case-series methodology explored data from all nationally reported laboratory-confirmed influenza cases. The proportion of reported cases occurring in vaccinees during an assumed unprotected phase after vaccination was compared with that occurring in vaccinees during their assumed protected phase. The test-negative case-control method included 1,749 pIV cases and 2,087 influenza test-negative individuals of whom 6 (0.3%) and 36 (1.7%), respectively, were vaccinated. The case series method included data from 73,280 cases. VE in the two methods was 79% (95% confidence interval (CI) = 35-93%; P = 0.007) and 87% (95% CI = 78-92%; P<0.001) for individuals less than 14 years of age and 70% (95% CI = -45%-94%, P = 0.13) and 74% (95% CI = 64-82%; P<0.001) for individuals above the age of 14. Both methods yielded similar VE in both age groups; and VE for the younger age group seemed to be higher.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uphoff</LastName><ForeName>Helmut</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hessisches Landes Prüfungs - und Untersuchungsamt im Gesundheitswesen, Dillenburg, Germany. h.uphoff@hlpug.hessen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An der Heiden</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schweiger</LastName><ForeName>Brunhilde</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Campe</LastName><ForeName>Hartmut</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Beier</LastName><ForeName>Dietmar</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Helmeke</LastName><ForeName>Carina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Littmann</LastName><ForeName>Martina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Haas</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Buda</LastName><ForeName>Silke</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Faensen</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Feig</LastName><ForeName>Marcel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Altmann</LastName><ForeName>Doris</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Wichmann</LastName><ForeName>Ole</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Eckmanns</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Buchholz</LastName><ForeName>Udo</ForeName><Initials>U</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>11</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>04</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21789163</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0019932</ArticleId><ArticleId IdType="pii">PONE-D-10-04520</ArticleId><ArticleId IdType="pmc">PMC3138735</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 Nov 13;58(44):1241-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19910912</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2011 Jan;8(1):e1000388</Citation><ArticleIdList><ArticleId IdType="pubmed">21379316</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Dec 17;361(25):2414-23</Citation><ArticleIdList><ArticleId IdType="pubmed">19846844</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2009 Dec 19;374(9707):2072-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19913290</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2010 Apr 1;201(7):984-92</Citation><ArticleIdList><ArticleId IdType="pubmed">20187740</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1994 Dec 7;272(21):1661-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7966893</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 1995 Nov;13(16):1522-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8578836</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Epidemiol. 1999 Feb;28(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10195657</ArticleId></ArticleIdList></Reference><Reference><Citation>Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006 Mar;49(3):287-95</Citation><ArticleIdList><ArticleId IdType="pubmed">16465515</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Commun Dis Rep. 2005 Sep 15;31(18):181-91</Citation><ArticleIdList><ArticleId IdType="pubmed">16669132</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2006 May 30;25(10):1768-97</Citation><ArticleIdList><ArticleId IdType="pubmed">16220518</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 Nov 10;24(44-46):6577-80</Citation><ArticleIdList><ArticleId IdType="pubmed">16842889</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Epidemiol. 2007 Jun;36(3):623-31</Citation><ArticleIdList><ArticleId IdType="pubmed">17403908</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Sep 12;26 Suppl 4:D17-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19230153</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2009 Aug 6;14(31). pii: 19288</Citation><ArticleIdList><ArticleId IdType="pubmed">19660248</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2009;339:b3928</Citation><ArticleIdList><ArticleId IdType="pubmed">19808768</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2010 Apr;7(4):e1000258</Citation><ArticleIdList><ArticleId IdType="pubmed">20386731</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2010 May 6;15(18). pii: 19561</Citation><ArticleIdList><ArticleId IdType="pubmed">20460094</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2011;16(2). pii: 19763</Citation><ArticleIdList><ArticleId IdType="pubmed">21251487</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Dec 17;361(25):2424-35</Citation><ArticleIdList><ArticleId IdType="pubmed">19745215</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000275 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000275 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeAllemagneV4
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:21789163
|texte= Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:21789163" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV4
| This area was generated with Dilib version V0.6.35. |  |